|
|
|
05.12.25 - 03:15
|
INNOVENT BIO Completes Introduction of Takeda, Raising ~HKD780M Net (AAStocks)
|
|
|
In October 2025, INNOVENT BIO (01801.HK) announced a global strategic partnership with Takeda Pharmaceutical (4502.JP). This partnership involves a licensing agreement valued at USD11.4 billion and a USD100 million strategic equity investment from Takeda.INNOVENT BIO announced that all conditions precedent to each of the license......
|
|
|
|
|
|
|
|
|
|
|
|
|
03.12.25 - 16:36
|
insitro Appoints R&D Veteran Stephen Hitchcock and AI Visionary Vijay Pande as Scientific Advisors (Business Wire)
|
|
|
Former Takeda CSO and a16z Bio + Health Founder to Guide Clinical Translation and Scaling of insitro's ChemML™ Platform
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, the AI therapeutics company built on causal biology, today announced the appointment of two scientific advisors: Stephen Hitchcock, Ph.D., a preeminent drug development leader and former Chief Scientific Officer of Takeda, and Vijay Pande, Ph.D., co-founder of VZVC and, previously, founder and General Partner of Andreessen Horowitz's Bio + Health fund.
Hitchcock and Pande will advise on the continued development and scaling of insitro's AI-driven ChemML™ platform as it is deployed across insitro's pipeline and partner programs. Their guidance will focus on translating compelling targets into the medicinal chemistry and preclinical development strategies required to advance therapeutics into clinical trials – connecting computational prediction with the realities of drug development at scale.
“Drug discovery often falters ...
|
|
|
02.12.25 - 22:45
|
New Data Presented at the Clinical Trials on Alzheimer′s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF (PR Newswire)
|
|
|
TOKYO and CAMBRIDGE, Mass., Dec. 2, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the latest data......
|
|
|
02.12.25 - 15:03
|
Swan EndoSurgical Appoints Veteran Robotics and MedTech Leader Erik Todd as Chief Executive Officer (Business Wire)
|
|
|
BOSTON--(BUSINESS WIRE)--Swan EndoSurgical, an emerging leader in flexible endoluminal surgical robotics, today announced the appointment of Erik Todd as its Chief Executive Officer. Erik joins Swan following more than 25 years of leadership at Stryker Corporation, where he most recently served as Vice President and General Manager of the Robotics and Enabling Technologies division.
Erik brings deep experience scaling next-generation robotic platforms, building high-performance global engineering organizations, and driving innovation across endoscopy, minimally invasive surgery, and digital/AI-enabled enabling technologies.
Swan EndoSurgical is backed by Revival Healthcare Capital and Olympus Corporation and is focused on delivering a fully integrated flexible endoluminal robotic platform for complex gastrointestinal interventions.
“Erik is an accomplished and respected leader in surgical robotics,” said Justin Ballotta, Managing Director at Revival Healthcare Capital and Head of Post-Investment Value...
|
|
|
|
|
02.12.25 - 14:06
|
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin (GlobeNewswire EN)
|
|
|
SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the first U.S. commercial sale of KOMZIFTI™ (ziftomenib) has been completed. Under Kura's collaboration and license agreement with Kyowa Kirin Co. Ltd. and Kyowa Kirin, Inc. (collectively, “Kyowa Kirin”), this milestone triggers a $135 million payment from Kyowa Kirin to Kura, which Kura expects to receive prior to year-end. KOMZIFTI was approved by the U.S. Food and Drug Administration on November 13, 2025....
|
|
|
|
|
|
|
|
|
|
|
01.12.25 - 15:06
|
Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO (Business Wire)
|
|
|
Industry veteran brings two decades of platform commercialization experience in cell therapy, bioprocessing, and bioanalytics as Cellares prepares to support multiple clinical trials in 2026
Appointment follows five global manufacturing agreements with partners, including Bristol Myers Squibb, Kite, and leading academic institutions, as well as the FDA's first Advanced Manufacturing Technology designation for a cell therapy manufacturing platform.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced the appointment of Ali Soleymannezhad as Chief Commercial Officer. Soleymannezhad, formerly Chief Commercial Officer at MaxCyte (NASDAQ: MXCT) and Executive Vice President at Tosoh Bioscience, will lead global commercial strategy as the company deploys its network of IDMO Smart Factories across the United States, Europe, and Japan. Soleymannezhad's appointment is key to driving the commercial expansion and pipeline gro...
|
|
|
01.12.25 - 12:36
|
Eisai seeks PMDA approval for subcutaneous Leqembi in Japan (PBR)
|
|
|
The formulation will serve as a new administration route. Eisai's application is based on data from several SC administration sub-studies of lecanemab, conducted within the Phase III Clarity
The post Eisai seeks PMDA approval for subcutaneous Leqembi in Japan appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
